Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, … Read more
Glycorex Transplantation AB (publ) (O33) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.006x
Based on the latest financial reports, Glycorex Transplantation AB (publ) (O33) has a cash flow conversion efficiency ratio of 0.006x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€233.00K) by net assets (€37.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Glycorex Transplantation AB (publ) - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Glycorex Transplantation AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Glycorex Transplantation AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glycorex Transplantation AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maxindo Karya Anugerah
JK:MAXI
|
0.018x |
|
Avensia publ AB
ST:AVEN
|
0.025x |
|
Torr Metals Inc
V:TMET
|
-0.011x |
|
Hannun SA
MC:HAN
|
-113.815x |
|
Capitea S.A.
WAR:CAP
|
0.111x |
|
TPC Consolidated Ltd
AU:TPC
|
0.228x |
|
Pico (Thailand) Public Company Limited
BK:PICO
|
0.155x |
|
Delorean Corporation Ltd
AU:DEL
|
-0.423x |
Annual Cash Flow Conversion Efficiency for Glycorex Transplantation AB (publ) (2021–2024)
The table below shows the annual cash flow conversion efficiency of Glycorex Transplantation AB (publ) from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €33.11 Million | €101.00K | 0.003x | +101.42% |
| 2023-12-31 | €44.04 Million | €-9.46 Million | -0.215x | -2469.23% |
| 2022-12-31 | €74.36 Million | €-622.00K | -0.008x | +0.17% |
| 2021-12-31 | €82.95 Million | €-695.00K | -0.008x | -- |